Morphine kills pain -- not patients

Mar 21, 2007

Many people, including health care workers, believe that morphine is a lethal drug that causes death when used to control pain for a patient who is dying. That is a misconception according to new research published in the latest issue of Palliative Medicine, from SAGE Publications.

Two articles in the peer-reviewed journal address research led by Professor Bassam Estfan of The Taussig Cancer Center in which patients in a specialist palliative care in-patient unit with severe cancer pain were treated with morphine, a type of opioid. Their vital statistics were monitored before and after the pain was controlled and there were no significant changes. Morphine did not cause respiratory depression, the mechanism by which lethal opioid overdose typically kills.

“Unlike many other drugs, morphine has a very wide safety margin,” wrote Dr Rob George, Consultant in Palliative Medicine, from the University College London, in his commentary about the research. “Evidence over the last 20 years has repeatedly shown that, used correctly, morphine is well tolerated, does not cloud the mind, does not shorten life, and its sedating effects wear off quickly. This is obviously good for patients in pain.”

“There is no evidence to suggest that morphine is a killer,” Dr George continued. “It could be perceived that not to give it is an act of brutality. We urge those in the medical community to understand the facts about morphine and other opioids – it’s time to set the record straight. Doctors should feel free to manage pain with doses adjusted to individual patients so that the patients can be comfortable and be able to live with dignity until they die.”

The articles, “Respiratory function during parenteral opioid titration for cancer pain” and, “Commentary: Lethal Opioids or dangerous prescribers?,” published by SAGE in the March issue of Palliative Medicine, are available at no charge for a limited time at pmj.sagepub.com/cgi/reprint/21/2/81 and pmj.sagepub.com/cgi/reprint/21/2/77.

Source: SAGE Publications

Explore further: Determine patient preferences by means of conjoint analysis

add to favorites email to friend print save as pdf

Related Stories

Death teaches US doctors lessons in art of living

Dec 24, 2010

Farrah Daly is a doctor who helps people die. The 33-year-old neurologist spends most of her days on the road. Her car's GPS is filled with the addresses of people who may have only days to live.

Common pain relief medication may encourage cancer growth

Nov 18, 2009

Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of ...

FDA reversal OKs morphine painkiller for dying

Apr 09, 2009

(AP) -- A liquid morphine painkiller given by family caregivers to dying patients can remain on the market, federal regulators have decided after hearing protests over their decision to remove it. The Food and Drug Administration ...

Using morphine to hasten death is a myth, says doctor

Mar 02, 2007

Using morphine to end a person's life is a myth, argues a senior doctor in a letter to this week's BMJ. It follows the case of Kelly Taylor, a terminally ill woman who went to court earlier this month for the right to be ...

Recommended for you

Determine patient preferences by means of conjoint analysis

20 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 0